No matching questions found
Try a different keyword or browse by topic in the sidebar.
Early signs include a new lump or thickening in the breast or armpit, changes in breast size or shape, nipple discharge (especially blood-stained), skin dimpling or puckering (resembling orange peel), redness or rash on the skin or around the nipple, and any new inversion of the nipple.
Not all lumps are cancerous, but any unusual change should be evaluated promptly. Regular self-examinations and annual mammograms (from age 40, or earlier if high-risk) are your first line of defense.
The most common types are invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC). We also see HER2-positive, triple-negative, hormone-receptor-positive, and in-situ (non-invasive) variants such as DCIS.
Yes — the type directly guides treatment. Hormone-receptor-positive cancers respond to hormone therapy; HER2-positive cancers benefit from targeted agents like trastuzumab; triple-negative breast cancer often requires aggressive chemotherapy. Genetic profiling tests (Oncotype DX, BRCA testing) further refine the personalized plan.
About 5–10% of breast cancers are hereditary, most commonly linked to BRCA1 or BRCA2 gene mutations. If you have two or more first-degree relatives with breast or ovarian cancer, or were diagnosed under 45, genetic counselling and testing are strongly recommended.
First-degree relatives (parents, siblings, children) of a BRCA mutation carrier have a 50% chance of carrying the same mutation and should consider testing. Preventive strategies — including enhanced surveillance or prophylactic surgery — can significantly reduce risk.
Treatment is multidisciplinary and individualized. It may combine surgery (lumpectomy or mastectomy), radiation therapy, chemotherapy, targeted therapy (for HER2+), and/or hormone therapy. The sequence — neoadjuvant (before surgery) versus adjuvant (after surgery) — depends on tumor size, stage, and biology. At Global Cancer Care, every plan is discussed in a multidisciplinary tumor board before being presented to you.
Yes. While smoking is the leading risk factor, approximately 10–15% of lung cancer patients worldwide are non-smokers. Other causes include radon gas exposure, secondhand smoke, air pollution, occupational carcinogens (asbestos, silica), and genetic mutations such as EGFR, ALK, ROS1, and RET rearrangements.
Non-smoker lung cancers are often adenocarcinomas and frequently harbor actionable driver mutations that respond very well to targeted therapy — making early genetic testing especially important.
Stage I–II: Cancer is localized; surgery (lobectomy) or stereotactic radiotherapy (SBRT) is often curative. Stage III: Locally advanced; treated with concurrent chemoradiation, often followed by consolidation immunotherapy. Stage IV: Metastatic; systemic therapy is the mainstay — targeted therapy for driver mutations, immunotherapy (anti-PD-1/PD-L1), or combination chemotherapy.
Even Stage IV lung cancer now offers meaningful survival gains with precision medicine. A comprehensive molecular profile (EGFR, ALK, PD-L1, KRAS, MET, RET, ROS1) is essential before starting treatment.
Yes — Stage I lung cancer carries a 5-year survival rate of 80–90% when completely resected. This underscores the value of screening. High-risk individuals (heavy smokers aged 50–80) are recommended annual low-dose CT (LDCT) scanning, which has been shown to reduce lung cancer mortality by over 20% compared to chest X-ray alone.
Key warning signs include: blood in or on the stool (bright red or dark/tarry), a persistent change in bowel habits lasting more than 4 weeks (diarrhea, constipation, or narrowing of stool), a feeling that the bowel doesn't empty completely, unexplained weight loss, persistent abdominal pain or cramping, and unexplained anemia causing fatigue.
Many early colorectal cancers produce no symptoms, which is why colonoscopy screening from age 45 (or earlier for high-risk individuals) is so important.
Absolutely. Evidence strongly supports: increasing dietary fiber (vegetables, fruits, whole grains), limiting red and processed meats, maintaining a healthy weight, regular physical activity, reducing alcohol consumption, and avoiding smoking. Regular aspirin use is being studied but should only be taken on medical advice given bleeding risks.
Molecular testing is now standard of care for metastatic colorectal cancer. RAS/BRAF mutation status determines eligibility for anti-EGFR therapy (cetuximab, panitumumab). MSI/MMR status identifies patients who may respond dramatically to immunotherapy (pembrolizumab). HER2 amplification and NTRK fusions open additional targeted options. At Global Cancer Care, comprehensive molecular profiling is performed for every eligible patient.
Leukemia arises in the bone marrow and blood, causing abnormal proliferation of white blood cells. It may be acute (fast-growing: ALL, AML) or chronic (slower: CLL, CML). Lymphoma starts in lymphocytes and primarily affects lymph nodes, spleen, and other lymphatic organs; the two broad categories are Hodgkin and Non-Hodgkin lymphoma. Multiple myeloma is cancer of plasma cells in the bone marrow, often causing bone pain, elevated calcium, and kidney problems.
Many hematologic cancers are highly treatable and many are curable. Hodgkin lymphoma is curable in over 80% of patients. ALL in children achieves cure rates exceeding 90%. CML is now managed as a chronic disease with targeted TKI therapy (imatinib, dasatinib), with patients achieving treatment-free remission. AML outcomes depend on cytogenetics and molecular markers, with stem cell transplant offering curative potential. Advances in CAR-T cell therapy and bispecific antibodies are further transforming outcomes.
Persistent fatigue or weakness, unexplained weight loss, drenching night sweats, recurrent infections, easy bruising or bleeding, painless swollen lymph nodes, bone pain, and an enlarged spleen or liver. Abnormal findings on a routine complete blood count (CBC) — very high or low white cell count, anemia, low platelets — also warrant urgent hematology evaluation.
Dr. Shingla has extensive experience managing pancreatic, hepatobiliary (liver, gallbladder, bile duct), gastric, esophageal, ovarian, cervical, endometrial, bladder, kidney, thyroid, head and neck, brain tumors (glioma, GBM), sarcomas, neuroendocrine tumors, and cancers of unknown primary origin.
For rare malignancies, molecular tumor profiling (comprehensive genomic profiling/CGP) is particularly valuable in identifying targetable alterations that may otherwise be missed.
CUP — where metastases are found but the original tumor site remains unclear — accounts for ~3% of all cancers. Comprehensive workup including CT PET scan, immunohistochemistry (IHC), and molecular tumor-of-origin testing (e.g., CancerSEEK, Oncotype DX CUP) can often identify the likely primary and guide site-specific treatment. Even when the primary remains unknown, molecular profiling frequently reveals actionable mutations (FGFR, NTRK, MSI-H) that allow effective targeted or immunotherapy.
Chemotherapy uses cytotoxic drugs to destroy cancer cells or stop them from dividing. It may be given intravenously (IV infusion), orally (tablets/capsules), or via injection. It is typically given in cycles — a treatment period followed by a rest period — allowing the body to recover while preventing cancer cell regrowth. The number of cycles, duration, and drugs used depend on cancer type, stage, and overall health.
Side effects vary by drug regimen but may include nausea and vomiting (well-controlled with modern antiemetics), fatigue, hair loss (temporary), mouth sores, reduced blood counts (increasing infection risk), peripheral neuropathy (tingling in hands/feet), and changes in appetite. Not every patient experiences all side effects — many patients work, travel, and maintain near-normal routines during treatment.
At Global Cancer Care, proactive symptom management and supportive care protocols are an integral part of every chemotherapy plan.
Hair loss (alopecia) occurs with some but not all chemotherapy regimens. Regimens commonly associated with hair loss include those containing anthracyclines (doxorubicin) and taxanes (paclitaxel, docetaxel). Oral regimens such as capecitabine or FOLFOX typically cause minimal to no hair loss. Hair almost always regrows — often with a different texture initially — after treatment ends. Scalp cooling (cold cap therapy) can reduce hair loss for some regimens and is available at our center.
The main categories include: checkpoint inhibitors (anti-PD-1/PD-L1: pembrolizumab, nivolumab, atezolizumab; anti-CTLA-4: ipilimumab), which release the immune system's "brakes"; CAR-T cell therapy (genetically engineered T cells targeting CD19, BCMA); cancer vaccines (sipuleucel-T for prostate cancer); cytokines (IL-2, interferons); and bispecific antibodies (blinatumomab, teclistamab). Each has specific indications and biomarker requirements.
Response is predicted by several biomarkers: PD-L1 expression (measured by IHC), tumor mutational burden (TMB), and microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR). High TMB and MSI-H are strong predictors of immunotherapy response across virtually all cancer types. Biomarker testing is performed from the tumor biopsy or, increasingly, from a liquid biopsy (ctDNA). Even patients with low PD-L1 sometimes respond — and sometimes combination approaches (chemo + immunotherapy) overcome initial resistance.
Surgery is recommended when the tumor is localized and technically resectable, when removing it offers the best chance of cure or long-term control, or for staging purposes (e.g., sentinel lymph node biopsy). It may also be performed for palliation — relieving obstruction, bleeding, or pain — even when cure is not the goal. Increasingly, neoadjuvant systemic therapy (chemotherapy or immunotherapy before surgery) is used to shrink tumors and improve surgical outcomes.
Minimally invasive approaches use small incisions, a camera (laparoscope), and specialized instruments or robotic systems (da Vinci) to remove cancerous tissue. Benefits include less blood loss, shorter hospital stay, faster recovery, and reduced post-operative pain compared to open surgery. These techniques are now standard for many colorectal, gynecologic, urologic, gastric, and thoracic cancers when technically feasible.
External beam radiation therapy (EBRT) delivers radiation from a machine outside the body to a precisely targeted area. Modern techniques include IMRT (intensity-modulated), VMAT, SBRT/SABR (stereotactic body radiation — high-dose in few sessions), and proton therapy. Brachytherapy places radioactive seeds or sources directly inside or near the tumor (used in prostate, cervical, endometrial, breast cancers). Both methods aim to maximize tumor dose while minimizing damage to surrounding healthy tissue.
The radiation treatment itself is painless — similar to having an X-ray. Side effects depend on the treatment site and dose. Common ones include skin redness/irritation at the treated area, fatigue, and localized tissue reactions (e.g., mouth sores with head and neck radiation, urinary symptoms with pelvic radiation). Most acute side effects resolve within weeks of completing treatment. Long-term side effects are minimized with precise modern planning techniques.
Chemotherapy attacks all rapidly dividing cells — both cancerous and healthy (which is why it causes broader side effects). Targeted therapy is designed to block specific molecular targets — proteins or genes — that drive cancer cell growth (e.g., EGFR in lung cancer, HER2 in breast cancer, BCR-ABL in CML). Because it acts more selectively, the side effect profile is different (often less hair loss and less nausea) though not absent. Its use requires the tumor to carry the relevant molecular alteration.
Acquired resistance is a challenge in targeted therapy. When it develops, we perform liquid biopsy or repeat tissue biopsy to identify the resistance mechanism (e.g., T790M mutation after 1st-gen EGFR TKI). Next-generation agents are often available (e.g., osimertinib for T790M+ NSCLC). If no further targetable alteration is found, switching to chemotherapy, immunotherapy, or clinical trials may be appropriate. The field is evolving rapidly — resistance mechanisms that had no solution a few years ago may now have approved therapies.
PDT is most commonly used for esophageal cancer, endobronchial (airway) cancer, Barrett's esophagus with dysplasia, superficial bladder cancer, skin cancers (basal cell carcinoma, Merkel cell), and some head and neck cancers. It requires light access to the tumor — either via endoscope, bronchoscope, or directly on the skin surface. PDT may be used as a primary treatment or to relieve obstruction/bleeding in advanced disease.
Yes — the photosensitizing drug (porfimer sodium/Photofrin) accumulates in all tissues for 4–6 weeks after injection. During this time, you must avoid direct sunlight and bright indoor lights to prevent serious skin burns and eye damage. You should stay indoors during peak sunlight hours, wear protective clothing and dark sunglasses if going out, and avoid bright examination or operating-room lights. This sensitivity is temporary and resolves as the drug clears from your body.
In an autologous transplant, your own stem cells are collected, stored, and re-infused after high-dose chemotherapy. This "rescues" your bone marrow and is used for multiple myeloma and certain lymphomas. In an allogeneic transplant, donor stem cells (from a matched sibling, unrelated donor, or cord blood) are infused after conditioning therapy. The donor immune system not only rebuilds the marrow but also provides a "graft-versus-leukemia/tumor" effect — attacking residual cancer cells. Allogeneic transplant is used for acute leukemias, MDS, aplastic anemia, and others, but carries the risk of graft-versus-host disease (GVHD).
Recovery takes several months and proceeds in phases. The first 2–4 weeks post-transplant involve neutropenia (very low white cells) and highest infection risk — typically managed as an inpatient or in a closely monitored outpatient setting. Engraftment (new marrow taking hold) usually occurs by day 14–28. Full immune reconstitution after allogeneic transplant may take 1–2 years. Most patients resume light activities within 3–6 months, though return to full normal life may take 6–12 months depending on complications and disease response.
Biologic therapies are derived from living organisms or engineered in the laboratory. They include monoclonal antibodies (bevacizumab targeting VEGF to block tumor blood supply; trastuzumab targeting HER2; rituximab targeting CD20 on B-cell lymphomas), antibody-drug conjugates (ADCs) that deliver cytotoxic payloads directly to cancer cells, and cytokines. Unlike traditional small-molecule drugs, biologics are large protein molecules that must be administered by injection or infusion and are more target-specific.
Yes — India has an active biosimilar market and several approved biosimilars for trastuzumab, bevacizumab, rituximab, and others, often at significantly lower cost than the originator products. Biosimilars are rigorously evaluated for comparable efficacy and safety. At Global Cancer Care, we discuss all available options — including biosimilars — to ensure treatment is both effective and financially accessible.
The two most common hormone-sensitive cancers are breast cancer (estrogen/progesterone receptor-positive: treated with tamoxifen, aromatase inhibitors — anastrozole, letrozole, exemestane — and CDK 4/6 inhibitors) and prostate cancer (androgen-sensitive: treated with LHRH agonists/antagonists, anti-androgens, and abiraterone/enzalutamide for advanced disease). Endometrial and some thyroid cancers may also be hormone-sensitive.
For early-stage hormone receptor-positive breast cancer, standard adjuvant hormone therapy is 5–10 years. Clinical trials have shown that extended therapy (up to 10 years) further reduces recurrence risk in higher-risk patients. For metastatic disease, hormone therapy is continued until disease progression. The choice of agent depends on menopausal status, prior therapy, and tolerability. Regular follow-up is essential during the treatment period.
Cryotherapy (cryoablation) uses extreme cold (liquid nitrogen or argon gas, reaching –40°C to –196°C) to freeze and destroy cancer cells. It is used for small prostate tumors (primary or salvage after radiation failure), kidney (renal cell) cancer, liver metastases, bone metastases for pain relief, cervical pre-cancer (CIN), and certain skin cancers. A probe is inserted into or near the tumor — often guided by ultrasound, CT, or MRI — to deliver the freezing agent. It is minimally invasive with a short recovery time.
Heating tumors to 40–44°C damages cancer cell proteins and DNA, impairs their ability to repair damage from radiation and chemotherapy, and increases blood flow and oxygen delivery to the tumor (which enhances radiation sensitivity). Clinical evidence supports hyperthermia combined with radiation for locally recurrent breast cancer, cervical cancer, soft tissue sarcomas, and rectal cancer. Whole-body hyperthermia is being explored for systemic effects. It is typically delivered using external microwave/radiofrequency applicators or implanted antenna probes.
Genetic counselling is recommended if you: were diagnosed with cancer at age 50 or younger, have two or more first-degree relatives with the same or related cancers, have a personal or family history of rare cancers (male breast cancer, ovarian cancer at any age, pancreatic cancer), have multiple primary cancers, or belong to a population with known higher carrier frequency (e.g., Ashkenazi Jewish ancestry for BRCA mutations). Our genetic counsellors help interpret results, explain risk percentages, and discuss prevention strategies for both you and your family.
Testing positive for BRCA1 or BRCA2 significantly increases breast and ovarian cancer risk, but there are clear risk-reduction strategies. These include: enhanced surveillance (annual MRI + mammogram from age 25–30), risk-reducing medications (tamoxifen, raloxifene), and risk-reducing surgery (prophylactic mastectomy reduces breast cancer risk by ~95%; prophylactic salpingo-oophorectomy reduces ovarian cancer risk by ~80%). The right strategy depends on your age, cancer history, family planning goals, and personal preferences — all explored during comprehensive counselling sessions.
Not all cancer patients experience severe pain, and when pain occurs, it can almost always be well-controlled. The WHO analgesic ladder provides a framework: starting with non-opioids (NSAIDs, paracetamol), advancing to weak opioids (tramadol, codeine), and then strong opioids (morphine, oxycodone, fentanyl) as needed. Adjuvant medications (steroids, anticonvulsants, antidepressants) target nerve pain. Interventional options include nerve blocks, intrathecal pumps, and radiation for bone pain. Early referral to pain management means you don't need to suffer unnecessarily.
This is one of the most common concerns, and it's important to distinguish physical dependence (normal, expected — the body adapts to opioids) from addiction (a behavioral disorder involving compulsive use despite harm). When opioids are used appropriately for cancer pain under medical supervision, the risk of addiction is very low. Your team will manage dosing carefully and taper medications when pain resolves. Please never allow fear of addiction to prevent you from seeking adequate pain relief.
Absolutely not. This is a very common misconception. Palliative care is specialized medical care focused on providing relief from symptoms, pain, and stress — it can and should be provided alongside curative or active treatment at any stage of illness. Research consistently shows that patients who receive early palliative care alongside active treatment not only have better quality of life but, in some studies, live longer than those who receive active treatment alone. It is about living as well as possible, not about dying sooner.
Palliative care addresses: pain, fatigue, breathlessness (dyspnea), nausea and vomiting, loss of appetite, constipation, anxiety, depression, sleep disturbances, lymphedema, and the emotional and spiritual distress that accompany a serious illness. The palliative care team includes physicians, nurses, social workers, chaplains, and other specialists working together with your oncology team.
Good nutrition during cancer treatment helps you maintain strength and energy, preserve muscle mass, tolerate treatment better with fewer dose reductions, support immune function, heal faster after surgery, and maintain quality of life. Malnutrition is associated with increased complications, longer hospitalizations, and poorer treatment outcomes. Many cancer and treatment-related symptoms (nausea, taste changes, mouth sores, diarrhea) can impair eating — our dietitian works to find practical strategies for each specific challenge.
During chemotherapy when immunity is low, a food-safe diet is important: avoid raw or undercooked meat, fish, and eggs; unpasteurized dairy and juices; raw sprouts; and improperly washed produce. Certain foods interact with specific drugs — for example, grapefruit inhibits enzymes that metabolize many cancer drugs (including some TKIs) and should be avoided. Supplements should also be reviewed by your oncologist — high-dose antioxidants (vitamin C, E) may theoretically interfere with some chemotherapy mechanisms. Our nutritionist and oncology team provide individualized food guidance based on your specific treatment regimen.
Completely normal — and very common. Studies show that up to 50% of cancer patients experience clinically significant anxiety or depression at some point during their illness. Fear of recurrence, changes in body image, financial stress, relationship strain, and uncertainty about the future are all real burdens. Acknowledging these feelings is not weakness — it is a natural response to a serious life event. Importantly, untreated psychological distress can reduce treatment adherence and quality of life, which is why addressing it is a medical priority, not a luxury.
Our psychosocial support services include individual counselling and psychotherapy (CBT, ACT), cancer-specific group support programs, social work assistance (financial guidance, insurance navigation, transport coordination), couple and family counselling, fertility preservation counselling (for younger patients before gonadotoxic treatment), and spiritual care. Referrals to psychiatry are available when medication for anxiety or depression is indicated. We believe healing the whole person — not just the tumor — is essential to the best outcomes.
Clinical trials offer access to cutting-edge treatments not yet commercially available — often drugs or combinations that outperform current standard of care. Participants receive: close monitoring and follow-up, investigational therapy often at no cost, the opportunity to contribute to progress that helps future patients, and access to internationally recognized oncology expertise. Clinical trials are not a "last resort" — many are offered as first-line treatment for newly diagnosed patients. Every approved cancer therapy we use today was once a clinical trial.
Phase I: First-in-human studies testing safety and dosing in small groups (20–80 patients). Phase II: Evaluates whether the treatment works against a specific cancer; looks at response rates (100–300 patients). Phase III: Large randomized trials comparing the new treatment to the current standard; results determine regulatory approval (hundreds to thousands of patients). Phase IV: Post-approval studies monitoring long-term safety and effectiveness in routine clinical practice. Dr. Shingla will explain which phase any proposed trial is in and what that means for your individual situation.
Yes — always. Participation in any clinical trial is entirely voluntary. You may withdraw at any time, for any reason, without penalty and without affecting the quality of your standard medical care. Before enrolling, you will complete a thorough informed consent process — a detailed review of the trial's purpose, procedures, potential risks and benefits, and alternatives. Take your time, ask all your questions, and involve your family in the decision.